Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany
Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany
美國以外的醫藥大麻銷售最暢銷，增長率達兩位數，重點放在德國。
InterCure Ltd. (NASDAQ:INCR) (TASE:INCR) reported its financial and operating results for the six months ended June 30, 2024. The Israeli-based cannabis operator posted revenue of NIS 126 million ($34.58 million), compared to NIS 147 million in the second half of 2023. The company noted that the October 7th terror attack affected the company's revenues in the first half of 2024 due to damages to its southern facility located at Kibbutz Nir Oz.
InterCure Ltd. (納斯達克：INCR) (特拉維夫證交所：INCR) 報告了截至2024年6月30日的半年財務和運營業績。這家以色列大麻運營商的營業收入爲1.26億新謝克爾（3458萬美元），而2023年下半年爲1.47億新謝克爾。該公司指出，10月7日的恐怖襲擊事件對其位於尼爾·奧茲基布斯（Kibbutz Nir Oz）的南方設施造成了損害，影響了2024年上半年的收入。
"Yesterday, we announced the expansion of our strategic partnership with Cookies to the German market, the largest market in Europe, which is experiencing accelerated growth and becoming a key target market for...
「昨天，我們宣佈將與維生餅乾（Cookies）擴展我們在德國市場...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。